Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay

Koivula, Minna; Richardson, Jill A.; Leino, Aila; Valleala, Heikki; Griffiths, Katie; Barnes, Alex; Konttinen, Yrjö T.; Garrity, M.L.; Risteli, Juha

doi:10.1016/j.clinbiochem.2010.09.019

Cited by 24 publications

(27 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, haemolysis caused a significant under-estimation of PINP, and caution should be exercised in reporting PINP results on haemolysed specimens. Our recovery and precision data agree well with those reported by Koivula et al, who also evaluated the IDS iSYS intact PINP assay [7]. By the use of gel-filtration studies, pooled sera and a haemodialysed serum, these authors found the assay to be specific for intact PINP.…”

Section: Discussionsupporting

confidence: 82%

“…According to the manufacturer and as corroborated by other studies, the assay had a within-and between-calibration CVs of < 3.7% and < 2.9% [7].…”

Section: Pinp Assaysmentioning

confidence: 63%

“…Repeated freezing and thawing of specimens did not have a significant influence on measured PINP values, and specimens stored at −20°C for up to 133 days gave PINP values that were not significantly different from the intact assay appears to be its specificity for PINP and its lack of cross-reactivity with the so-called monomeric or other forms [5,12]. The identities of these molecules are unknown; they may be either pro-α1 chains or fragments of PINP, but they have also been reported to have a larger molecular weight than PINP [7]. The retention of some of these molecules in blood of patients with renal impairment can make the interpretation of some total PINP results difficult [5].…”

Section: Discussionmentioning

confidence: 99%

“…An automated total PINP immunoassay (Roche Diagnostics) has been available for some years [6], and in 2009, an automated chemiluminometric immunoassay for intact PINP was made available by Immunodiagnostic Systems Ltd (IDS) on their iSYS analyser. An evaluation of this assay and analyser was undertaken recently by Koivula et al, who also evaluated the intact PINP assay results in patients with renal failure, and compared the values with those obtained by the Roche E170 total PINP assay [7]. In the current bicentre study, we have carried out additional independent evaluations of the iSYS intact PINP assay, and have established reference intervals for both children and adults.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children

Morovat

Catchpole

Meurisse

et al. 2013

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: We carried out a technical evaluation of the Immunodiagnostic Systems (IDS) automated intact procollagen-I N-terminus propeptide (PINP) assay on the iSYS platform, and established reference intervals for PINP in both adults and children. Methods: Assay imprecision, recovery and interference were studied. Serum and plasma values were compared, and PINP stability was assessed. Using 828 specimens, IDS iSYS intact PINP and Roche E170 total PINP values were compared. Specimens from 597 adults and 485 children and adolescents were used to establish reference intervals for intact PINP. Results: The method demonstrated good recovery and acceptable imprecision. The assay was unaffected by icterus and lipaemia, but haemolysis decreased measured PINP. Serum and plasma values were comparable. There was a non-linear relation between IDS intact and Roche total PINP values. Pre-and post-menopausal women had comparable PINP values, but there was a difference between women of different age groups. Serum PINP in men showed a decline in young age up to 45 years, but remained steady thereafter. Separate reference intervals were established for four age groups in women and for two age groups in men. Data for children were partitioned into four-year age groups, and these showed PINP to be high with no major gender differences until 12 years of age. Thereafter, values in females decreased in 13-16 years age groups and further in 17-20 years age groups, whereas PINP increased in boys of 13-16 years of age with a subsequent decline at 17-20 years. Conclusions: The IDS iSYS PINP intact assay appears to be reliable. We have established gender-and age-related reference intervals for children and adults based on a relatively large healthy North European population.

show abstract

Section: Discussionsupporting

confidence: 82%

“…According to the manufacturer and as corroborated by other studies, the assay had a within-and between-calibration CVs of < 3.7% and < 2.9% [7].…”

Section: Pinp Assaysmentioning

confidence: 63%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children

Morovat

Catchpole

Meurisse

et al. 2013

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…8 The assay is based on chemiluminescence technology (CLIA). Measurements were carried out in a single analysis according to the manufacturer's kit insert instructions during May 2010.…”

Section: Automated Assay Of Intact Pinpmentioning

confidence: 99%

Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases

et al. 2011

View full text Add to dashboard Cite

show abstract

Rapid cortical bone loss in patients with chronic kidney disease

Nickolas

Stein

Dworakowski

et al. 2013

Journal of Bone and Mineral Research

272

247

View full text Add to dashboard Cite

Chronic kidney disease (CKD) patients may have high rates of bone loss and fractures, but microarchitectural and biochemical mechanisms of bone loss in CKD patients have not been fully described. In this longitudinal study of 53 patients with CKD Stages 2-5D, we used dual energy X-ray absorptiometry (DXA), high resolution peripheral quantitative computed tomography (HRpQCT) and biochemical markers of bone metabolism to elucidate effects of CKD on the skeleton. Median follow-up was 1.5 years (Range 0.9 to 4.3 years); bone changes were annualized and compared to baseline. By DXA, there were significant declines in areal bone mineral density (BMD) of the total hip and ultradistal radius: −1.3% (95% CI: −2.1 to −0.6) and −2.4% (95% CI: −4.0 to −0.9), respectively. By HRpQCT at the distal radius, there were significant declines in cortical area, density and thickness, and increases in porosity: −2.9% (95% CI −3.7 to −2.2), −1.3% (95% CI −1.6 to −0.6), −2.8% (95% CI −3.6 to −1.9), and +4.2% (95% CI 2.0 to 6.4) respectively. Radius trabecular area increased significantly: +0.4% (95% CI 0.2 to 0.6), without significant changes in trabecular density or microarchitecture. Elevated time-averaged levels of parathyroid hormone (PTH) and bone turnover markers predicted cortical deterioration. Higher levels of serum 25-hydroxyvitamin D predicted decreases in trabecular network heterogeneity. These data suggest that significant cortical loss occurs with CKD, which is mediated by hyperparathyroidism and elevated turnover. Future investigations are required to determine whether these cortical losses can be attenuated by treatments that reduce PTH levels and remodeling rates.

show abstract

Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay

Cited by 24 publications

References 11 publications

IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children

IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children

Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases

Rapid cortical bone loss in patients with chronic kidney disease

Contact Info

Product

Resources

About